Russell Investments Group
BCAX

Russell Investments Group’s Bicara Therapeutics BCAX Stock Holding History

Russell Investments Group’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$396K Sell
19,893
-36,705
-65% -$632K ﹤0.01% 2593
2025
Q4 		$953K Buy
56,598
+17,472
+45% +$298K ﹤0.01% 2237
2025
Q3 		$618K Buy
39,126
+11,654
+42% +$130K ﹤0.01% 2390
2025
Q2 		$255K Buy
+27,472
New +$327K ﹤0.01% 2577

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Russell Investments Group's BCAX Position: Q1 2026 in Review

Russell Investments Group reduced its Bicara Therapeutics (BCAX) stake by 65% in Q1 2026, selling an estimated $632K and leaving 19,893 shares worth $396K. The position accounts for ﹤0.01% of the portfolio, ranked #2593.

Russell Investments Group first reported a position in BCAX in Q2 2025 and has held it in 4 quarters since. The position peaked at $953K in Q4 2025. 146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

  • Russell Investments Group held 19,893 shares of Bicara Therapeutics worth $396K as of Q1 2026.
  • Russell Investments Group sold 36,705 Bicara Therapeutics shares in Q1 2026, an estimated $632K.
  • Bicara Therapeutics made up ﹤0.01% of Russell Investments Group's portfolio in Q1 2026, its #2593 holding.
  • Russell Investments Group first reported a position in Bicara Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Russell Investments Group's Bicara Therapeutics position peaked at $953K in Q4 2025.
  • 146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on Russell Investments Group's 13F filing for Q1 2026, filed 8 May 2026.